Még nem toboroz
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483· 3. fázis· Forrás
Toboroz
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
NCT07691970· 3. fázis· Forrás
Toboroz
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· 3. fázis· Forrás
Toboroz
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
NCT07662213· 3. fázis· Forrás
Toboroz
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
NCT07764978· 3. fázis· Forrás
Toboroz
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
NCT07710885· 3. fázis· Forrás
Toboroz
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
NCT07529717· 1/2. fázis· Forrás
Toboroz
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
NCT07611110· 3. fázis· Forrás
Toboroz
A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants
NCT07454291· 1. fázis· Forrás
Toboroz
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657· 3. fázis· Forrás
Fut, nem toboroz
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
NCT07336446· 1/2. fázis· Forrás
Toboroz
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809· 3. fázis· Forrás
Toboroz
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
NCT07224373· 1. fázis· Forrás
Toboroz
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
NCT07109219· 1/2. fázis· Forrás
Toboroz
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336· 3. fázis· Forrás
Fut, nem toboroz
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136· 3. fázis· Forrás
Toboroz
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
NCT06897930· 1/2. fázis· Forrás
Toboroz
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038· 1/2. fázis· Forrás
Toboroz
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
NCT06312644· Forrás
Toboroz
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
NCT06542250· 1/2. fázis· Forrás
Fut, nem toboroz
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197· 2. fázis· Forrás
Toboroz
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751· 3. fázis· Forrás
Fut, nem toboroz
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931· 3. fázis· Forrás
Toboroz
Observational Study Protocol: LIVER-R
NCT06252753· Forrás
Toboroz
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941· 2. fázis· Forrás
Toboroz
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945· 1/2. fázis· Forrás
Toboroz
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864· 3. fázis· Forrás
Fut, nem toboroz
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491· 3. fázis· Forrás
Fut, nem toboroz
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728· 3. fázis· Forrás
Toboroz
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168· 1/2. fázis· Forrás
Fut, nem toboroz
Study to Assess SLN124 in Patients With Polycythemia Vera
NCT05499013· 1/2. fázis· Forrás
Fut, nem toboroz
First in Human Study of AZD9592 in Solid Tumors
NCT05647122· 1. fázis· Forrás
Toboroz
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
NCT05536141· 1. fázis· Forrás
Toboroz
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT05417594· 1/2. fázis· Forrás
Fut, nem toboroz
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
NCT05367440· 1/2. fázis· Forrás
Toboroz
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT05123482· 1/2. fázis· Forrás
Fut, nem toboroz
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
NCT04995523· 1/2. fázis· Forrás
Fut, nem toboroz
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
NCT04594642· 1. fázis· Forrás
Fut, nem toboroz
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
NCT04538742· 1/2. fázis· Forrás
Fut, nem toboroz
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
NCT04556773· 1. fázis· Forrás
Fut, nem toboroz
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068· 1/2. fázis· Forrás
Fut, nem toboroz
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
NCT04590963· 3. fázis· Forrás
Fut, nem toboroz
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309· 2. fázis· Forrás
Fut, nem toboroz
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04269200· 3. fázis· Forrás
Fut, nem toboroz
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
NCT04068610· 1/2. fázis· Forrás
Fut, nem toboroz
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
NCT04035486· 3. fázis· Forrás
Fut, nem toboroz
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261· 3. fázis· Forrás
Fut, nem toboroz
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03778957· 3. fázis· Forrás
Fut, nem toboroz
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
NCT03732677· 3. fázis· Forrás
Fut, nem toboroz
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
NCT03530397· 1. fázis· Forrás